NDAINTRAVENOUS, ORALSOLUTIONPriority Review
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
Carbapenemase-Producing Organism and Vancomycin-Resistant Enterococcus Management
Started Feb 2022
3,921 enrolled
Multidrug-resistant Bacteria Screening
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
Started Jan 2021
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
Started Jun 2019
4 enrolled
Clostridium Difficile Infection Recurrence
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
Started Oct 2018
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Started May 2017
144 enrolled
Clostridium Difficile Infection (CDI)
Loss of Exclusivity
LOE Date
Nov 6, 2035
117 months away
Patent Expiry
Nov 6, 2035
Company
Hikma
NJ - Berkeley Heights
External Resources